Clinical Trial Search

Primary: Count of Participants With Positive and Negative 18F-FDG PET CT and F18-NaF PET CT Imaging Results in Individuals With MGUS, SMM, and MM. — 0; 1; 5; 10 Participants

Primary: Percentage of Patients With MRD(-) Remissions at the Completion of Consolidation Therapy — 81.4 percentage of patients achieving MRD (-)

Primary: Proportion of Subjects With a Downgraded Risk of Progression of Smoldering Multiple Myeloma if the Risk Category Decreases. — 0 proportion of participants

Primary: 2 Year Progression Free Percent — 62.5 percentage of participants

Primary: Percentage of Participants With Minimal Residual Disease (MRD)Negative Complete Response (CR) Per International Myeloma Working Group (IMWG) Criteria — 70.4 percentage…

Primary: Intervention Attendance (Feasibility) — 50 percentage of participants

Primary: One-Year Progression-Free Survival (PFS) Rate — 84.5; 74.4 Percentage of participants

Primary: Number of Multiple Myeloma (MM) Participants Categorized by Clinical Characteristics — 342; 366; 48; 36 Participants

Primary: Bone Formation Markers Measurement — 21.87; 23.2; 1.33; 28.75 U/L — p=0.002

Primary: Overall Response Rate (ORR) — 1; 1; 7; 1 participants

Primary: Increase in ENK (Expanded Natural Killer Cells) Cells 7 Days After Treatment — 0 Participants

Primary: Fraction of Patients (n=3) for Whom a sdAb Could be Generated That Binds to the Idiotype of the Paraprotein. — 2 Participants

Primary: Percentage of MM Participants Categorized by Sociodemographic Variables at Diagnosis — 100; 53.3; 46.7; 100 percentage of participants

Primary: Number of Participants Achieving a Complete Response — 51 Participants

Primary: Maximum Tolerated (MTD) Dose of Cyclophosphamide With Ixazomib and Dexamethasone (Phase I) — 4; 40 mg weekly

Primary: Feasibility of Obtaining Baseline Clinical and PRO Data Capture From 200 Consented Patients. — 196 Participants

Primary: Median Progression Free Survival (mPFS) — 76.4 months

Primary: The Percent of Patients With Minimal Residual Disease (MRD) Status Changing to Negative at Day 100 (Post-AHCT), Among Patients With MRD Positive at the End of Induction…

Primary: Rate of Patients Achieving an Objective Response — 0; 0 participants

Primary: Complete Response or Partial Response Based on M-Protein Assessments Only — 0; 0 Participants

Primary: The Number of Participants With a Significant Increase in Serum Creatinine at 12 Months — 17; 13 Participants

Primary: Changes in M-protein Levels — 1.65; 2.24 g/dL — p=.23

Primary: Linear Regression of Maximal Percent Reduction in Serum Monoclonal (M) Protein on Baseline Percent CD56^Dim Cells in Bone Marrow — -2.562; 2.464; 0.274 % chg from BL in…

Primary: Number of Participants Without Renal Allograft Rejection at 6 Months Post-transplant — 1 Participants

Primary: Percent of Patients Who Are Progression Free at 2 Years — 45.0; 36.4 percentage of participants

Primary: Frequency of Symptomatic Venous Thromboembolism — 0 Participants

Primary: Symptom Reduction — 26.02; 26.65 units on a scale*month

Primary: The Number of Patients That Achieve Complete Response — 7 Participants

Primary: Therapeutic Efficacy — 1 Participants

Primary: Progression Free Survival (PFS) Rate at 2 Years After Enrollment in Untreated Patients With Multiple Myeloma. — 84.6; 83.3 percentage of participants